Rafferty Asset Management, LLC Albireo Pharma, Inc. Transaction History

Rafferty Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$18.54 - $37.29 $142,257 - $286,126	7,673 Added 15.32%	57,758 $1.15 Million
Q1 2022 May 13, 2022	SELL	$23.94 - $33.74 $340,019 - $479,209	-14,203 Reduced 22.09%	50,085 $1.49 Million
Q4 2021 Feb 10, 2022	BUY	$21.19 - $31.29 $476,139 - $703,086	22,470 Added 53.73%	64,288 $1.5 Million
Q3 2021 Nov 10, 2021	BUY	$27.36 - $35.98 $316,418 - $416,108	11,565 Added 38.23%	41,818 $1.31 Million
Q2 2021 Aug 10, 2021	SELL	$28.9 - $36.87 $551,267 - $703,295	-19,075 Reduced 38.67%	30,253 $1.06 Million

Q1 2021 May 10, 2021	BUY	$32.03 - $42.85 $1.34 Million - $1.79 Million	41,775 Added 553.09%	49,328 $1.74 Million
Q4 2020 Feb 10, 2021	BUY	$31.56 - $42.16 $238,372 - $318,434	7,553 New	7,553 $283,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.